CANTARGIA AB
556791-6019ActiveDeveloping antibody-based drugs targeting IL1RAP for serious diseases.
Oversigt
- 20–49
- Medarbejdere
- ≤1t SEK
- Omsætning
- 2009
- Grundlagt
Nøglebeslutningstagere
Hilde H. Steineger
CEO
Wolfram Dempke
Chief Medical Officer
Magnus Persson
Chairman of the Board
Damian Marron
Board Member
+6 flere kontakter i Funnelfeedr
Beskrivelse
Cantargia is a biotechnology company focused on developing innovative antibody-based therapeutics. Their primary scientific target is the protein IL1RAP, which plays a role in several serious conditions. The company's mission is to create treatments for cancer as well as autoimmune and inflammatory...
Tags
Nøgleord
Teknologistak
Virksomhedsoplysninger
- Branche
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- Momsnummer
- SE556791601901
Beslutningstagere
10 kontakter i FunnelfeedrHilde H. Steineger
CEO
Wolfram Dempke
Chief Medical Officer
Magnus Persson
Chairman of the Board
Damian Marron
Board Member
Patrik Renblad
CFO
Flavia Borellini
Board Member
Ton Berkien
CBO
David Liberg
CSO
Jenny Sundqvist
Board Member
Anders Martin-Löf
Board Member
Lignende virksomheder
20 lignende virksomheder i FunnelfeedrHamlet BioPharma AB
5–9 medarbejdereInnovative pharmaceutical company developing targeted cancer and infection treatments.
Alligator Bioscience AB
10–19 medarbejdereClinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
Beactica Therapeutics AB
5 medarbejderePrecision medicine company developing novel therapeutics via targeted protein degradation.
BioGaia Pharma AB
0 medarbejdereDeveloping and out-licensing novel biotherapeutic platforms from microbiome research.
Nanohumps Biosciences Oy
Pioneering revolutionary cancer therapies using proprietary nanosized antibodies.
Udforsk mere
Spørgsmål om CANTARGIA AB
Vil du se Funnelfeedr i aktion?
Book en gratis demo og opdag, hvordan Funnelfeedr hjælper dig med at finde og konvertere dine ideelle kunder.
Book en demo